Your browser doesn't support javascript.
loading
Retinoic acid receptor activation reprograms senescence response and enhances anti-tumor activity of natural killer cells.
Colucci, Manuel; Zumerle, Sara; Bressan, Silvia; Gianfanti, Federico; Troiani, Martina; Valdata, Aurora; D'Ambrosio, Mariantonietta; Pasquini, Emiliano; Varesi, Angelica; Cogo, Francesca; Mosole, Simone; Dongilli, Cristina; Desbats, Maria Andrea; Contu, Liliana; Revankdar, Ajinkya; Chen, Jingjing; Kalathur, Madhuri; Perciato, Maria Luna; Basilotta, Rossella; Endre, Laczko; Schauer, Stefan; Othman, Alaa; Guccini, Ilaria; Saponaro, Miriam; Maraccani, Luisa; Bancaro, Nicolò; Lai, Ping; Liu, Lei; Pernigoni, Nicolò; Mele, Federico; Merler, Sara; Trotman, Lloyd C; Guarda, Greta; Calì, Bianca; Montopoli, Monica; Alimonti, Andrea.
Afiliación
  • Colucci M; Institute of Oncology Research (IOR), CH6500 Bellinzona, Switzerland; Università della Svizzera Italiana, CH6900 Lugano, Switzerland; Faculty of Biology and Medicine, University of Lausanne UNIL, CH1011 Lausanne, Switzerland.
  • Zumerle S; Veneto Institute of Molecular Medicine (VIMM) & Department of Medicine, University of Padova, Padova, Italy.
  • Bressan S; Institute of Oncology Research (IOR), CH6500 Bellinzona, Switzerland; Università della Svizzera Italiana, CH6900 Lugano, Switzerland; Veneto Institute of Molecular Medicine (VIMM) & Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy.
  • Gianfanti F; Institute of Oncology Research (IOR), CH6500 Bellinzona, Switzerland; Università della Svizzera Italiana, CH6900 Lugano, Switzerland; Veneto Institute of Molecular Medicine (VIMM) & Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy.
  • Troiani M; Institute of Oncology Research (IOR), CH6500 Bellinzona, Switzerland; Università della Svizzera Italiana, CH6900 Lugano, Switzerland; Bioinformatics Core Unit, Swiss Institute of Bioinformatics, TI, Bellinzona, Switzerland.
  • Valdata A; Institute of Oncology Research (IOR), CH6500 Bellinzona, Switzerland; Department of Health Sciences and Technology (D-HEST) ETH Zurich, Zurich, CH, Switzerland.
  • D'Ambrosio M; Institute of Oncology Research (IOR), CH6500 Bellinzona, Switzerland; MRC London Institute of Medical Sciences (LMS), London, UK.
  • Pasquini E; Institute of Oncology Research (IOR), CH6500 Bellinzona, Switzerland; Università della Svizzera Italiana, CH6900 Lugano, Switzerland.
  • Varesi A; Institute of Oncology Research (IOR), CH6500 Bellinzona, Switzerland; Università della Svizzera Italiana, CH6900 Lugano, Switzerland.
  • Cogo F; Institute of Oncology Research (IOR), CH6500 Bellinzona, Switzerland; Università della Svizzera Italiana, CH6900 Lugano, Switzerland.
  • Mosole S; Institute of Oncology Research (IOR), CH6500 Bellinzona, Switzerland; Università della Svizzera Italiana, CH6900 Lugano, Switzerland.
  • Dongilli C; Institute of Oncology Research (IOR), CH6500 Bellinzona, Switzerland; Università della Svizzera Italiana, CH6900 Lugano, Switzerland.
  • Desbats MA; Veneto Institute of Molecular Medicine (VIMM) & Department of Medicine, University of Padova, Padova, Italy.
  • Contu L; Veneto Institute of Molecular Medicine (VIMM) & Department of Medicine, University of Padova, Padova, Italy.
  • Revankdar A; Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA 02129, USA.
  • Chen J; Department of Cell Biology, Harvard Medical School, Boston, MA 02215, USA; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
  • Kalathur M; Children's GMP, LLC, St. Jude Children's Research Hospital, 262 Danny Thomas Place Mail Stop 920 Memphis, TN 38105, USA.
  • Perciato ML; School of Clinical Dentistry, University of Sheffield, Sheffield S10 2TA, UK.
  • Basilotta R; Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, 98166 viale Ferdinando D'Alcontres, Italy.
  • Endre L; Functional Genomics Center Zurich, ETHZ and University of Zurich, Zurich, CH, Switzerland.
  • Schauer S; Functional Genomics Center Zurich, ETHZ and University of Zurich, Zurich, CH, Switzerland.
  • Othman A; Functional Genomics Center Zurich, ETHZ and University of Zurich, Zurich, CH, Switzerland.
  • Guccini I; Department of Health Sciences and Technology (D-HEST) ETH Zurich, Zurich, CH, Switzerland.
  • Saponaro M; Veneto Institute of Molecular Medicine (VIMM) & Department of Medicine, University of Padova, Padova, Italy.
  • Maraccani L; Institute of Oncology Research (IOR), CH6500 Bellinzona, Switzerland; Veneto Institute of Molecular Medicine (VIMM) & Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy.
  • Bancaro N; Institute of Oncology Research (IOR), CH6500 Bellinzona, Switzerland; Università della Svizzera Italiana, CH6900 Lugano, Switzerland.
  • Lai P; Institute of Oncology Research (IOR), CH6500 Bellinzona, Switzerland; Università della Svizzera Italiana, CH6900 Lugano, Switzerland.
  • Liu L; Institute of Oncology Research (IOR), CH6500 Bellinzona, Switzerland; Università della Svizzera Italiana, CH6900 Lugano, Switzerland.
  • Pernigoni N; Institute of Oncology Research (IOR), CH6500 Bellinzona, Switzerland; Università della Svizzera Italiana, CH6900 Lugano, Switzerland.
  • Mele F; Institute for Research in Biomedicine, Università della Svizzera Italiana, Bellinzona, Switzerland.
  • Merler S; Section of Innovation Biomedicine - Oncology Area, Department of Engineering for Innovation Medicine, University of Verona and Verona University and Hospital Trust, Verona, Italy.
  • Trotman LC; Cold Spring Harbor Laboratory, One Bungtown Road, Cold Spring Harbor, NY 11724, USA.
  • Guarda G; Institute for Research in Biomedicine, Università della Svizzera Italiana, Bellinzona, Switzerland.
  • Calì B; Institute of Oncology Research (IOR), CH6500 Bellinzona, Switzerland; Università della Svizzera Italiana, CH6900 Lugano, Switzerland.
  • Montopoli M; Veneto Institute of Molecular Medicine (VIMM) & Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy.
  • Alimonti A; Institute of Oncology Research (IOR), CH6500 Bellinzona, Switzerland; Università della Svizzera Italiana, CH6900 Lugano, Switzerland; Veneto Institute of Molecular Medicine (VIMM) & Department of Medicine, University of Padova, Padova, Italy; Department of Health Sciences and Technology (D-HEST)
Cancer Cell ; 42(4): 646-661.e9, 2024 Apr 08.
Article en En | MEDLINE | ID: mdl-38428412
ABSTRACT
Cellular senescence can exert dual effects in tumors, either suppressing or promoting tumor progression. The senescence-associated secretory phenotype (SASP), released by senescent cells, plays a crucial role in this dichotomy. Consequently, the clinical challenge lies in developing therapies that safely enhance senescence in cancer, favoring tumor-suppressive SASP factors over tumor-promoting ones. Here, we identify the retinoic-acid-receptor (RAR) agonist adapalene as an effective pro-senescence compound in prostate cancer (PCa). Reactivation of RARs triggers a robust senescence response and a tumor-suppressive SASP. In preclinical mouse models of PCa, the combination of adapalene and docetaxel promotes a tumor-suppressive SASP that enhances natural killer (NK) cell-mediated tumor clearance more effectively than either agent alone. This approach increases the efficacy of the allogenic infusion of human NK cells in mice injected with human PCa cells, suggesting an alternative therapeutic strategy to stimulate the anti-tumor immune response in "immunologically cold" tumors.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Senescencia Celular Límite: Animals / Humans / Male Idioma: En Revista: Cancer Cell Asunto de la revista: NEOPLASIAS Año: 2024 Tipo del documento: Article País de afiliación: Suiza Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Senescencia Celular Límite: Animals / Humans / Male Idioma: En Revista: Cancer Cell Asunto de la revista: NEOPLASIAS Año: 2024 Tipo del documento: Article País de afiliación: Suiza Pais de publicación: Estados Unidos